{"filing":{"accession_number":"0001104659-26-094440","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2622949d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926094440/tm2622949d1_8k.htm"},"events":[{"id":27019,"run_id":24586,"accession_number":"0001104659-26-094440","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Humacyte issued a press release on August 12, 2026 disclosing financial results for its fiscal second quarter ended June 30, 2026, including commercial sales of Symvess ($0.4M Q2 2026 vs. $0.1M Q2 2025), net loss ($36.8M Q2 2026 vs. $37.7M Q2 2025), and cash position ($80.3M as of June 30, 2026). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics and operational highlights material to investor assessment.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28361,"accession_number":"0001104659-26-094440","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Humacyte issued a press release on August 12, 2026 disclosing financial results for its fiscal second quarter ended June 30, 2026, including commercial sales of Symvess ($0.4M Q2 2026 vs. $0.1M Q2 2025), net loss ($36.8M Q2 2026 vs. $37.7M Q2 2025), and cash position ($80.3M as of June 30, 2026). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics and operational highlights material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:25.866842+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28361,"accession_number":"0001104659-26-094440","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Humacyte issued a press release on August 12, 2026 disclosing financial results for its fiscal second quarter ended June 30, 2026, including commercial sales of Symvess ($0.4M Q2 2026 vs. $0.1M Q2 2025), net loss ($36.8M Q2 2026 vs. $37.7M Q2 2025), and cash position ($80.3M as of June 30, 2026). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics and operational highlights material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:05:25.866842+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-08-12"}]}